Acne is a multifactorial disease involving the colonization of skin follicles by Cutibacterium (formerly Propionibacterium) acnes. A combination of different retinoid-derived products, antibiotics, and hormonal antiandrogens are used to treat the disease, but these treatments require extended periods, may have secondary effects, are expensive, and not always effective. Owing to antibiotic resistance, the use of bacteriophages has been proposed as an alternative treatment. However, if they are intended for a cosmetic or pharmaceutical use, it is necessary to evaluate the safety of the phages and the preparations containing them.
Materials and Methods:
In this study, the cytotoxicity of Pa.7 bacteriophage was evaluated in HaCaT cells, along with a liposome suitable for their encapsulation, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and trypan blue assays.
Results:
We found that Pa.7 was not cytotoxic for HaCaT cells. Also, 30 mM of liposomes, or below are considered noncytotoxic concentrations.
Conclusion:
Phages encapsulated in the liposomes presented in this study can be used safely for skin treatments.
Get full access to this article
View all access options for this article.
References
1.
AshkenaziH, MalikZ, HarthY, et al.Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol, 2003; 35(1):17–24; doi: 10.1111/j.1574-695x.2003.tb00644.x
2.
ToyodaM, MorohashiM. Pathogenesis of acne. Med Electron Microsc, 2001; 34:29–40; doi: 10.1007/s007950100002
3.
ShawJC.Acne: Effect of hormones on pathogenesis and management. Am J Clin Dermatol, 2002; 3:571–578; doi: 10.2165/00128071-200203080-00007
4.
PochiPE, StraussJS, DowningDT. Skin surface lipid composition, acne, pubertal development, and urinary excretion of testosterone and 17 ketosteroids in children. J Invest Dermatol, 1977; 69(5):485–489; doi: 10.1111/1523-1747.ep12511753
5.
TitusS, HodgeJ. Diagnosis and treatment of acne. Am Fam Physician, 2012; 86(8):734–740.
HalvorsenJA, SternRS, DalgardF, et al.Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: A population-based study. J Invest Dermatol, 2011; 131(2):363–370; doi: 10.1038/jid.2010.264
8.
CunliffeWJ.Acne and unemployment. Br J Dermatol, 1986; 115:386–386; doi: 10.1111/j.1365-2133.1986.tb05757.x
9.
FarfánJ, GonzalezJM, VivesM. The immunomodulatory potential of phage therapy to treat acne: A review on bacterial lysis and immunomodulation. PeerJ, 2022; 10:e13553; doi: 10.7717/peerj.13553
10.
LeydenJJ, Rosso JQDel, BaumEW. The use of isotretinoin in the treatment of acne vulgaris: Clinical considerations and future directions. J Clin Aesthet Dermatol, 2014; 7(2 Suppl):S3–S21.
11.
BrzezinskiP, BorowskaK, ChiriacA, et al.Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther, 2017; 30(4):e12483; doi: 10.1111/dth.12483
12.
StrahanJE, RaimerS. Isotretinoin and the controversy of psychiatric adverse effects. Int J Dermatol, 2006; 45:789–799; doi: 10.1111/j.1365-4632.2006.02660.x
13.
HeT, LiH, ZhangX. Deep-sea hydrothermal vent viruses compensate for microbial metabolism in virus-host interactions. mBio, 2017; 8(4):e00893-17; doi: 10.1128/mBio.00893-17
14.
Ly-ChatainMH.The factors affecting effectiveness of treatment in phages therapy. Front Microbiol, 2014; 5:1–7; doi: 10.3389/fmicb.2014.00051
15.
KimMJ, EunDH, KimSM, et al.Efficacy of bacteriophages in Propionibacterium acnes-induced inflammation in mice. Ann Dermatol, 2019; 31(1):22–28; doi: 10.5021/ad.2019.31.1.22
16.
LamHY, LaiM-J, ChenT-Y, et al.Therapeutic effect of a newly isolated lytic bacteriophage against multi-drug-resistant Cutibacterium acnes infection in mice. Int J Mol Sci, 2021; 22(13):7031; doi: 10.3390/ijms22137031
17.
Loc-CarrilloC, AbedonST. Pros and cons of phage therapy. Bacteriophage, 2011; 1(2):111–114; doi: 10.4161/bact.1.2.14590
18.
NilssonAS.Phage therapy-constraints and possibilities. Ups J Med Sci, 2014; 119(2):192–198; doi: 10.3109/03009734.2014.902878
19.
LeónM, BastíasR.Virulence reduction in bacteriophage resistant bacteria. Front Microbiol, 2015; 6:343; doi: 10.3389/fmicb.2015.00343
20.
JończykE, KłakM, MiędzybrodzkiR, et al.The influence of external factors on bacteriophages-review. Folia Microbiol (Praha), 2011; 56(3):191–200; doi: 10.1007/s12223-011-0039-8
21.
ChristensenGJM, BrüggemannH. Bacterial skin commensals and their role as host guardians. Benef Microbes, 2014; 5(2):201–215; doi: 10.3920/BM2012.0062
22.
KurokawaI, DanbyFW, JuQ, et al.New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol, 2009; 18(10):821–832; doi: 10.1111/j.1600-0625.2009.00890.x
23.
VandenheuvelD, LavigneR, BrüssowH. Bacteriophage therapy: Advances in formulation strategies and human clinical trials. Annu Rev Virol, 2015; 2(1):599–618; doi: 10.1146/annurev-virology-100114-054915
24.
AkbarzadehA, Rezaei-SadabadyR, DavaranS, et al.Liposome: Classification, preparation, and applications. Nanoscale Res Lett, 2013; 8(1):1–9; doi: 10.1186/1556-276X-8-102
25.
WangDY, van der MeiHC, RenY, et al.Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections. Front Chem, 2020; 7:872; doi: 10.3389/fchem.2019.00872
SinglaS, HarjaiK, KatareOP, et al.Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS One, 2016; 11(4):e0153777; doi: 10.1371/journal.pone.0153777
28.
BernauerU, BodinL, ChaudhryQ, et al.The SCCS notes of guidance for the testing of cosmetic ingredients and their safety evaluation, 11th revision, 30–31 March 2021, SCCS/1628/21. Regul Toxicol Pharmacol, 2021; 127:105052; doi: 10.1016/j.yrtph.2021.105052.
29.
AvciP, SadasivamM, GuptaA, et al.Animal models of skin disease for drug discovery. Expert Opin Drug Discov, 2013:8:331–355; doi: 10.1517/17460441.2013.761202
30.
LiuD, van BelleghemJD, de VriesCR, et al.The safety and toxicity of phage therapy: A review of animal and clinical studies. Viruses, 2021; 13(7):1268; doi: 10.3390/v13071268
31.
PirnayJ-P, BlasdelBG, BretaudeauL, et al.Quality and safety requirements for sustainable phage therapy products. Pharm Res, 2015; 32(7):2173–2179; doi: 10.1007/s11095-014-1617-7
32.
BaqueroUrizaDP, Prada PeñaradaC, Suesca SanchezE, et al.Topical compositions comprising bacteriophages encapsulated in liposomes [in Spanish]. Colombia Patent NC2018/0008178. 2020.
33.
BaqueroUrizaDP. Isolation and characterization of Colombian native Propionibacterium acnes bacteriophages [in Spanish] [Thesis]. Uniandes; 2014. Available from: https://repositorio.uniandes.edu.co/handle/1992/16462 [Last accessed: February 25, 2023].
34.
Silva QuinteroLM. Isolation and genomic characterization of Propionibacterium acnes specific bacteriophages [in Spanish] [Masters Thesis]. Uniandes; 2015. Available from: https://repositorio.uniandes.edu.co/handle/1992/13156 [Last accessed: February 25, 2023].
35.
KropinskiAM, MazzoccoA, WaddellTE, et al.Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol, 2009; 501:69–76; doi: 10.1007/978-1-60327-164-6_7
36.
ColomJ, Cano-SarabiaM, OteroJ, et al.Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol, 2015; 81(14):4841–4849; doi: 10.1128/AEM.00812-15
37.
StroberW.Trypan blue exclusion test of cell viability. Curr Protoc Immunol, 2015; 111:A3.B.1–A3.B.3; doi: 10.1002/0471142735.ima03bs111
38.
ShanJ, RamachandranA, ThankiAM, et al.Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells. Sci Rep, 2018; 8(1):5091; doi: 10.1038/s41598-018-23418-y
39.
MayJE, XuJ, MorseHR, et al.Toxicity testing: The search for an in vitro alternative to animal testing. Br J Biomed Sci, 2009; 66:160–165; doi: 10.1080/09674845.2009.11730265
40.
International Organization for Standard. ISO 10993-5:2009—Biological Evaluation of Medical Devices—Part 5: Tests for In Vitro Cytotoxicity, 3rd ed. International Organization for Standardization: Geneva, Switzerland; 2009.
41.
AyarigaJA, GildeaL, WuH, et al.The E34 phage tailspike protein: An in vitro characterization, structure prediction, potential interaction with S. newington LPS and cytotoxicity assessment to animal cell line. bioRxiv, 2021;09.20.461090; doi: 10.1101/2021.09.20.461090
42.
Topka-BieleckaG, Nejman-FaleńczykB, BlochS, et al.Phage–bacteria interactions in potential applications of bacteriophage vb_efas-271 against enterococcus faecalis. Viruses, 2021; 13(2):318; doi: 10.3390/v13020318
43.
MeloLDR, FerreiraR, CostaAR, et al.Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model. Sci Rep, 2019; 9(1):6643; doi: 10.1038/s41598-019-43115-8
44.
HeneinAE, HanlonGW, CooperCJ, et al.A partially purified Acinetobacter baumannii phage preparation exhibits no cytotoxicity in 3T3 mouse fibroblast cells. Front Microbiol, 2016; 7:1198; doi: 10.3389/fmicb.2016.01198
45.
PorayathC, SalimA, PalillamVeeduA, et al.Characterization of the bacteriophages binding to human matrix molecules. Int J Biol Macromol, 2018; 110:608–615; doi: 10.1016/j.ijbiomac.2017.12.052
46.
De CavanaghEM, FerderM, InserraF, et al.Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: An integrating viewpoint. Am J Physiol Heart Circ Physiol, 2009; 296:H550–H558; doi: 10.1152/ajpheart.01176.2008
47.
MalikDJ, SokolovIJ, VinnerGK, et al.Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci, 2017; 249:100–133; doi:10.1016/j.cis.2017.05.014
48.
AlaviM, RaiM, VarmaRS, et al.Conventional and novel methods for the preparation of micro and nanoliposomes. Micro Nano Bio Aspects, 2022; 1(1):18–29.
49.
ChhibberS, KaurJ, KaurS. Liposome entrapment of bacteriophages improves wound healing in a diabetic mouse MRSA infection. Front Microbiol, 2018; 9:561; doi: 10.3389/fmicb.2018.00561
50.
ChangRYK, MoralesS, OkamotoY, et al.Topical application of bacteriophages for treatment of wound infections. Transl Res, 2020; 220:153–166; doi: 10.1016/j.trsl.2020.03.010
51.
CinquerruiS, MancusoF, VladisavljevićGT, et al.Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front Microbiol, 2018; 9:2172; doi: 10.3389/fmicb.2018.02172
52.
AltmanSA, RandersL, RaoG. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog, 1993; 9(6):671–674; doi: 10.1021/bp00024a017
53.
BulbakeU, DoppalapudiS, KommineniN, et al.Liposomal formulations in clinical use: An updated review. Pharmaceutics, 2017; 9:12; doi: 10.3390/pharmaceutics9020012
54.
LvH, ZhangS, WangB, et al.Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release, 2006; 114:100–109; doi: 10.1016/j.jconrel.2006.04.014
55.
KellyC, JefferiesC, CryanS-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv, 2011; 2011:727241; doi: 10.1155/2011/727241
56.
NagayasuA, UchiyamaK, KiwadaH. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev, 1999; 40(1–2):75–87; doi: 10.1016/S0169-409X(99)00041-1
57.
JończykE, ŁodejN, KulaD, et al.Factors determining phage stability/activity: Challenges in practical phage application. Expert Rev Anti Infect Ther, 2019; 17(8):583–606; doi: 10.1080/14787210.2019.1646126
58.
MayhewE, ItoM, LazoR. Toxicity of non-drug-containing liposomes for cultured human cells. Exp Cell Res, 1987; 171(1):195–202; doi: 10.1016/0014-4827(87)90262-x
